CME Medical Grand Rounds ~ Considerations for Optimizing Transplant in Multiple Myeloma Patient Mana

EVENT DETAILS AND REGISTRATION

Date:September 06, 2016

Time: 12:00 PM - 01:00 PM (PT)

Location:Conference Room B

Event Is:

  • Identify factors that might determine eligibility for and timing of high-dose chemotherapy (HDT) followed by autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma
  • Differentiate treatment strategies for patients with newly diagnosed multiple myeloma who are eligible for HDT/ASCT
  • Review the rationale for conditioning regimens in patients with multiple myeloma who are eligible for HDT/ASCT
  • Compare and contrast pertinent data regarding a new formulation of melphalan

Presenters:Omar Aljitawi, MD

ADDITIONAL DETAILS:

Objectives:

  • Identify factors that might determine eligibility for and timing of high-dose chemotherapy (HDT) followed by autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma
  • Differentiate treatment strategies for patients with newly diagnosed multiple myeloma who are eligible for HDT/ASCT
  • Review the rationale for conditioning regimens in patients with multiple myeloma who are eligible for HDT/ASCT
  • Compare and contrast pertinent data regarding a new formulation of melphalan

Who should attend:

Physicians, nurses, pharmacy and clinical coordinators that perform transplants for multiple myeloma patients.

Sponsor(s):Educational Grant from Spectrum Pharmaceuticals

CME credits:1.0 AMA/PRA Category 1 Credit™ The City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. City of Hope designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.TM

R.S.V.P.: First Come First Serve

Contact:

CME Department